Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861
Abstract
:1. Introduction
2. Results
2.1. Production of Obinutuzumab-Dianthin (ObiDi)
2.2. Cytotoxicity of ObiDi on Raji and Jurkat Cell Lines
2.3. Efficacy of ObiDi/SO1861 in a Lymphoma Mouse Tumor Model
3. Discussion
4. Conclusions
5. Materials and Methods
5.1. Recombinant Expression and Purification of Dianthin
5.2. Chemical Conjugation and Purification of ObiDi
5.3. Cell Culture
5.4. Cytotoxicity Evaluation by XTT End-Point Assay
5.5. Raji B-Cell Lymphoma Xenotransplantation Model
5.6. Immunotherapy of B-Cell Lymphoma Xenograft-Bearing Mice
5.7. Bioluminescent Imaging of Tumor Development
5.8. Hematological Analysis
5.9. Isolation of SO1861
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
References
- Payandeh, Z.; Bahrami, A.A.; Hoseinpoor, R.; Mortazavi, Y.; Rajabibazl, M.; Rahimpour, A.; Taromchi, A.H.; Khalil, S. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed. Pharmacother. 2019, 109, 2415–2426. [Google Scholar] [CrossRef] [PubMed]
- Robak, T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin. Investig. Drugs 2009, 10, 588–596. [Google Scholar] [PubMed]
- Dhillon, S. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma. Target Oncol. 2017, 12, 255–262. [Google Scholar] [CrossRef] [PubMed]
- Luan, C.; Chen, B. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia. Drug Des. Devel. Ther. 2019, 13, 2899–2909. [Google Scholar] [CrossRef]
- O’Nions, J.; Townsend, W. The role of obinutuzumab in the management of follicular lymphoma. Future Oncol. 2019, 15, 3565–3578. [Google Scholar] [CrossRef]
- Tobinai, K.; Klein, C.; Oya, N.; Fingerle-Rowson, G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv. Ther. 2017, 34, 324–356. [Google Scholar] [CrossRef]
- Honeychurch, J.; Alduaij, W.; Azizyan, M.; Cheadle, E.J.; Pelicano, H.; Ivanov, A.; Huang, P.; Cragg, M.S.; Illidge, T.M. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012, 119, 3523–3533. [Google Scholar] [CrossRef]
- Cheadle, E.J.; Sidon, L.; Dovedi, S.J.; Melis, M.H.; Alduaij, W.; Illidge, T.M.; Honeychurch, J. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. Br. J. Haematol. 2013, 162, 842–845. [Google Scholar] [CrossRef]
- Kawasaki, N.; Yamashita-Kashima, Y.; Fujimura, T.; Yoshiura, S.; Harada, N.; Kondoh, O.; Yoshimura, Y. Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Mol. Biol. Rep. 2022, 49, 4421–4433. [Google Scholar] [CrossRef]
- Yamashita-Kashima, Y.; Yorozu, K.; Fujimura, T.; Kawasaki, N.; Kurasawa, M.; Yoshiura, S.; Harada, N.; Kondoh, O.; Yoshimura, Y. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors. Int. J. Hematol. 2022, 115, 860–872. [Google Scholar] [CrossRef]
- Hess, G.; Huttmann, A.; Witzens-Harig, M.; Dreyling, M.H.; Keller, U.; Marks, R.; Ernst, T.; Pott, C.; Viardot, A.; Frontzek, F.; et al. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br. J. Haematol. 2022. [Google Scholar] [CrossRef]
- Klein, C.; Bacac, M.; Umana, P.; Fingerle-Rowson, G. Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert. Opin. Investig. Drugs 2017, 26, 1145–1162. [Google Scholar] [CrossRef]
- Kutsch, N.; Pallasch, C.; Tausch, E.; Bohme, V.; Ritgen, M.; Liersch, R.; Wacker, A.; Jacobs, G.; Trappe, R.U.; Dreger, P.; et al. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere 2022, 6, e692. [Google Scholar] [CrossRef]
- Moreno, C.; Greil, R.; Demirkan, F.; Tedeschi, A.; Anz, B.; Larratt, L.; Simkovic, M.; Novak, J.; Strugov, V.; Gill, D.; et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica 2022. [Google Scholar] [CrossRef]
- Li, M.; Liu, Z.S.; Liu, X.L.; Hui, Q.; Lu, S.Y.; Qu, L.L.; Li, Y.S.; Zhou, Y.; Ren, H.L.; Hu, P. Clinical targeting recombinant immunotoxins for cancer therapy. Onco. Targets Ther. 2017, 10, 3645–3665. [Google Scholar] [CrossRef]
- Trail, P.A. Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins. In Antibody-Drug Conjugates and Immunotoxins; Phillips, G., Ed.; Springer: New York, NY, USA, 2013. [Google Scholar]
- Khongorzul, P.; Ling, C.J.; Khan, F.U.; Ihsan, A.U.; Zhang, J. Antibody-Drug Conjugates: A Comprehensive Review. Mol. Cancer Res. 2020, 18, 3–19. [Google Scholar] [CrossRef]
- Amoroso, A.; Hafsi, S.; Militello, L.; Russo, A.E.; Soua, Z.; Mazzarino, M.C.; Stivala, F.; Libra, M. Understanding rituximab function and resistance: Implications for tailored therapy. Front. Biosci. 2011, 16, 770–782. [Google Scholar] [CrossRef]
- Flavell, D.J.; Warnes, S.; Noss, A.; Flavell, S.U. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Cancer Res. 1998, 58, 5787–5794. [Google Scholar]
- Gilabert-Oriol, R.; Thakur, M.; von Mallinckrodt, B.; Hug, T.; Wiesner, B.; Eichhorst, J.; Melzig, M.F.; Fuchs, H.; Weng, A. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. Mol. Pharm. 2013, 10, 4347–4357. [Google Scholar] [CrossRef]
- Amitai, I.; Gafter-Gvili, A.; Shargian-Alon, L.; Raanani, P.; Gurion, R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol. Oncol. 2021, 39, 215–221. [Google Scholar] [CrossRef]
- Huang, S.; Jiang, C.; Zhang, H.; Bell, T.; Guo, H.; Liu, Y.; Yao, Y.; Zeng, D.; Ahmed, M.; Nomie, K.; et al. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J. 2018, 8, 33. [Google Scholar] [CrossRef] [PubMed]
- Borthakur, G.; Rosenblum, M.G.; Talpaz, M.; Daver, N.; Ravandi, F.; Faderl, S.; Freireich, E.J.; Kadia, T.; Garcia-Manero, G.; Kantarjian, H.; et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 2013, 98, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Fuchs, H. Dianthin and Its Potential in Targeted Tumor Therapies. Toxins 2019, 11, 592. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Furness, S.G.B.; Stringer, B.W.; Weng, A.; Fuchs, H.; Day, B.W.; Kourakis, A.; Boyd, A.W.; Hare, D.L.; Thakur, M.; et al. Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma. Cancer Immunol. Immunother. 2017, 66, 1217–1228. [Google Scholar] [CrossRef] [PubMed]
- Polito, L.; Mercatelli, D.; Bortolotti, M.; Maiello, S.; Djemil, A.; Battelli, M.G.; Bolognesi, A. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells. Toxins 2017, 9, 182. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Weng, A.; Mallinckrodt, B.; Melzig, M.F.; Fuchs, H.; Thakur, M. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: A lethal cocktail with tumor specific efficacy. Curr. Pharm. Des. 2014, 20, 6584–6643. [Google Scholar] [CrossRef]
- Schrot, J.; Weng, A.; Melzig, M.F. Ribosome-inactivating and related proteins. Toxins 2015, 7, 1556–1615. [Google Scholar] [CrossRef]
- Rihova, B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 1998, 29, 273–289. [Google Scholar] [CrossRef]
- Fitzgerald, D. Why toxins! Semin. Cancer Biol. 1996, 7, 87–95. [Google Scholar] [CrossRef]
- Fuchs, H.; Niesler, N.; Trautner, A.; Sama, S.; Jerz, G.; Panjideh, H.; Weng, A. Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. Biomedicines 2017, 5, 14. [Google Scholar] [CrossRef]
- Bhargava, C.; Durkop, H.; Zhao, X.; Weng, A.; Melzig, M.F.; Fuchs, H. Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861. Mol. Oncol. 2017, 11, 1527–1543. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Weng, A.; Trautner, A.; Weise, C.; Schmid, D.; Bhargava, C.; Niesler, N.; Wookey, P.J.; Fuchs, H.; Thakur, M. Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861. Biochem. Pharmacol. 2015, 97, 247–255. [Google Scholar] [CrossRef] [PubMed]
- Sama, S.; Woith, E.; Walther, W.; Jerz, G.; Chen, W.; Hart, S.; Melzig, M.F.; Weng, A. Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma. J. Control. Release 2018, 275, 208–216. [Google Scholar] [CrossRef] [PubMed]
- Zarinwall, A.; Asadian-Birjand, M.; Seleci, D.A.; Maurer, V.; Trautner, A.; Garnweitner, G.; Fuchs, H. Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861. Nanomaterials 2021, 11, 1057. [Google Scholar] [CrossRef]
- Weng, A.; Thakur, M.; von Mallinckrodt, B.; Beceren-Braun, F.; Gilabert-Oriol, R.; Wiesner, B.; Eichhorst, J.; Bottger, S.; Melzig, M.F.; Fuchs, H. Saponins modulate the intracellular trafficking of protein toxins. J. Control. Release 2012, 164, 74–86. [Google Scholar] [CrossRef]
- Böttger, S.; Melzig, M.F. The influence of saponins on cell membrane cholesterol. Bioorg. Med. Chem. 2013, 21, 7118–7124. [Google Scholar] [CrossRef]
- Thakur, M.; Mergel, K.; Weng, A.; von Mallinckrodt, B.; Gilabert-Oriol, R.; Durkop, H.; Melzig, M.F.; Fuchs, H. Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice. Mol. Oncol. 2013, 7, 475–483. [Google Scholar] [CrossRef]
- von Mallinckrodt, B.; Thakur, M.; Weng, A.; Gilabert-Oriol, R.; Durkop, H.; Brenner, W.; Lukas, M.; Beindorff, N.; Melzig, M.F.; Fuchs, H. Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma. Future Oncol. 2014, 10, 2161–2175. [Google Scholar] [CrossRef]
- Holmes, S.E.; Bachran, C.; Fuchs, H.; Weng, A.; Melzig, M.F.; Flavell, S.U.; Flavell, D.J. Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent. Immunopharmacol. Immunotoxicol. 2015, 37, 42–55. [Google Scholar] [CrossRef]
- Bortolotti, M.; Bolognesi, A.; Battelli, M.G.; Polito, L. High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin. Toxins 2016, 8, 192. [Google Scholar] [CrossRef]
- Polito, L.; Bolognesi, A.; Tazzari, P.L.; Farini, V.; Lubelli, C.; Zinzani, P.L.; Ricci, F.; Stirpe, F. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 2004, 18, 1215–1222. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Thakur, M.; Haussmann, K.; Niesler, N.; Bhargava, C.; Gorick, C.; Fuchs, H.; Weng, A. Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin. Planta. Med. 2016, 82, 1525–1531. [Google Scholar] [CrossRef] [PubMed]
- Sefid, F.; Alagheband Bahrami, A.; Payandeh, Z.; Khalili, S.; Azamirad, G.; Kalantar, S.M.; Touhidinia, M. Ofatumumab and Granzyme B as immunotoxin against CD20 antigen. Silico Pharmacol. 2022, 10, 6. [Google Scholar] [CrossRef] [PubMed]
- Weng, A. A novel adenine-releasing assay for ribosome-inactivating proteins. J. Chromatogr. B Analyt. Technol Biomed. Life Sci. 2018, 1072, 300–304. [Google Scholar] [CrossRef]
- Weng, A.; Thakur, M.; Beceren-Braun, F.; Bachran, D.; Bachran, C.; Riese, S.B.; Jenett-Siems, K.; Gilabert-Oriol, R.; Melzig, M.F.; Fuchs, H. The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins. Mol. Oncol. 2012, 6, 323–332. [Google Scholar] [CrossRef]
- Trautner, A. Mechanismen der Zielgerichteten Antitumoralen Wirksamkeit von Dianthin-Panitumumab-Konjugaten in Kombination Mit dem Glykosylierten Triterpenoid SO1861; Freie Universität Berlin: Berlin, Germany, 2021. [Google Scholar]
- Garcia-Perez, B.E.; De la Cruz-Lopez, J.J.; Castaneda-Sanchez, J.I.; Munoz-Duarte, A.R.; Hernandez-Perez, A.D.; Villegas-Castrejon, H.; Garcia-Latorre, E.; Caamal-Ley, A.; Luna-Herrera, J. Macropinocytosis is responsible for the uptake of pathogenic and non-pathogenic mycobacteria by B lymphocytes (Raji cells). BMC Microbiol. 2012, 12, 246. [Google Scholar] [CrossRef]
- Zhang, M.; Zhu, Q.; Shi, M.; Liu, Y.; Ma, L.; Yang, Y.; Feng, D.; Dai, W.; Zhang, L.; Kang, T.; et al. Active phagocytosis of Mycobacterium tuberculosis (H37Ra) by T lymphocytes (Jurkat cells). Mol. Immunol. 2015, 66, 429–438. [Google Scholar] [CrossRef]
- Vago, R.; Marsden, C.J.; Lord, J.M.; Ippoliti, R.; Flavell, D.J.; Flavell, S.U.; Ceriotti, A.; Fabbrini, M.S. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J. 2005, 272, 4983–4995. [Google Scholar] [CrossRef]
- Weng, A.; Bachran, C.; Fuchs, H.; Melzig, M.F. Soapwort saponins trigger clathrin-mediated endocytosis of saporin, a type I ribosome-inactivating protein. Chem. Biol. Interact. 2008, 176, 204–211. [Google Scholar] [CrossRef]
- Bolognesi, A.; Polito, L.; Scicchitano, V.; Orrico, C.; Pasquinelli, G.; Musiani, S.; Santi, S.; Riccio, M.; Bortolotti, M.; Battelli, M.G. Endocytosis and intracellular localisation of type 1 ribosome-inactivating protein saporin-s6. J. Biol. Regul. Homeost. Agents 2012, 26, 97–109. [Google Scholar]
- Chu, T.W.; Zhang, R.; Yang, J.; Chao, M.P.; Shami, P.J.; Kopecek, J. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics 2015, 5, 834–846. [Google Scholar] [CrossRef] [PubMed]
- O’Donnell, R.T.; Ma, Y.; McKnight, H.C.; Pearson, D.; Tuscano, J.M. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol. Immunother. 2009, 58, 2051–2058. [Google Scholar] [CrossRef]
- Smith, E.J.; Olson, K.; Haber, L.J.; Varghese, B.; Duramad, P.; Tustian, A.D.; Oyejide, A.; Kirshner, J.R.; Canova, L.; Menon, J.; et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci. Rep. 2015, 5, 17943. [Google Scholar] [CrossRef] [PubMed]
- Moolten, F.L.; Cooperband, S.R. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970, 169, 68–70. [Google Scholar] [CrossRef] [PubMed]
- Moolten, F.; Zajdel, S.; Cooperband, S. Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin. Ann. N. Y. Acad. Sci. 1976, 277, 690–699. [Google Scholar] [CrossRef] [PubMed]
- Jansen, F.K.; Blythman, H.E.; Carriere, D.; Casellas, P.; Gros, O.; Gros, P.; Laurent, J.C.; Paolucci, F.; Pau, B.; Poncelet, P.; et al. Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol. Rev. 1982, 62, 185–216. [Google Scholar] [CrossRef]
- Hertler, A.A.; Frankel, A.E. Immunotoxins: A clinical review of their use in the treatment of malignancies. J. Clin. Oncol. 1989, 7, 1932–1942. [Google Scholar] [CrossRef]
- Baldo, B.A. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies 2022, 11, 17. [Google Scholar] [CrossRef]
- Fuchs, H.; Weng, A.; Gilabert-Oriol, R. Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers. Toxins 2016, 8, 200. [Google Scholar] [CrossRef]
- Fabbrini, M.S.; Rappocciolo, E.; Carpani, D.; Solinas, M.; Valsasina, B.; Breme, U.; Cavallaro, U.; Nykjaer, A.; Rovida, E.; Legname, G.; et al. Characterization of a saporin isoform with lower ribosome-inhibiting activity. Biochem. J. 1997, 322, 719–727. [Google Scholar] [CrossRef]
- Geden, S.E.; Gardner, R.A.; Fabbrini, M.S.; Ohashi, M.; Phanstiel Iv, O.; Teter, K. Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate. FEBS J. 2007, 274, 4825–4836. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.H.; Lim, I.; Woo, S.K.; Kim, W.; Kim, K.I.; Lee, K.C.; Song, K.; Lim, S.M. Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: Dosimetry estimate of (225)Ac-DOTA-rituximab using (64)Cu-DOTA-rituximab. Ann. Nucl. Med. 2021, 35, 639–647. [Google Scholar] [CrossRef] [PubMed]
- Herter, S.; Herting, F.; Mundigl, O.; Waldhauer, I.; Weinzierl, T.; Fauti, T.; Muth, G.; Ziegler-Landesberger, D.; Van Puijenbroek, E.; Lang, S.; et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 2013, 12, 2031–2042. [Google Scholar] [CrossRef] [PubMed]
- Mossner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115, 4393–4402. [Google Scholar] [CrossRef]
- Byrd, J.C.; Flynn, J.M.; Kipps, T.J.; Boxer, M.; Kolibaba, K.S.; Carlile, D.J.; Fingerle-Rowson, G.; Tyson, N.; Hirata, J.; Sharman, J.P. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016, 127, 79–86. [Google Scholar] [CrossRef]
- Cartron, G.; de Guibert, S.; Dilhuydy, M.S.; Morschhauser, F.; Leblond, V.; Dupuis, J.; Mahe, B.; Bouabdallah, R.; Lei, G.; Wenger, M.; et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: Final data from the phase 1/2 GAUGUIN study. Blood 2014, 124, 2196–2202. [Google Scholar] [CrossRef]
- Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C.M.; Chagorova, T.; de la Serna, J.; Dilhuydy, M.S.; Illmer, T.; et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 2014, 370, 1101–1110. [Google Scholar] [CrossRef]
- Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2, 750–763. [Google Scholar] [CrossRef]
- Press, O.W.; Martin, P.J.; Thorpe, P.E.; Vitetta, E.S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol. 1988, 141, 4410–4417. [Google Scholar]
- Kato, Y.; Seita, T.; Kuwabara, T.; Sugiyama, Y. Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: Use of RME as a drug delivery system. J. Control. Release 1996, 39, 191–200. [Google Scholar] [CrossRef]
- Freeman, C.L.; Sehn, L.H. A tale of two antibodies: Obinutuzumab versus rituximab. Br. J. Haematol. 2018, 182, 29–45. [Google Scholar] [CrossRef] [PubMed]
- Fuchs, H.; Bachran, C.; Li, T.; Heisler, I.; Durkop, H.; Sutherland, M. A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J. Control. Release 2007, 117, 342–350. [Google Scholar] [CrossRef] [PubMed]
- Bachran, D.; Schneider, S.; Bachran, C.; Urban, R.; Weng, A.; Melzig, M.F.; Hoffmann, C.; Kaufmann, A.M.; Fuchs, H. Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int. J. Cancer 2010, 127, 1453–1461. [Google Scholar] [CrossRef]
- Heisler, I.; Sutherland, M.; Bachran, C.; Hebestreit, P.; Schnitger, A.; Melzig, M.F.; Fuchs, H. Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. J. Control. Release 2005, 106, 123–137. [Google Scholar] [CrossRef]
- Gilabert-Oriol, R.; Thakur, M.; von Mallinckrodt, B.; Bhargava, C.; Wiesner, B.; Eichhorst, J.; Melzig, M.F.; Fuchs, H.; Weng, A. Reporter assay for endo/lysosomal escape of toxin-based therapeutics. Toxins 2014, 6, 1644–1666. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Thakur, M.; Weise, C.; Dernedde, J.; von Mallinckrodt, B.; Fuchs, H.; Weng, A. Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression. Protein. Expr. Purif. 2013, 91, 54–60. [Google Scholar] [CrossRef] [PubMed]
- Panjideh, H.; Müller, G.; Koch, M.; Wilde, F.; Scheu, S.; Moldenhauer, G.; Lipp, M. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model. Int. J. Cancer 2014, 135, 2623–2632. [Google Scholar] [CrossRef] [PubMed]
- Gilabert-Oriol, R.; Mergel, K.; Thakur, M.; von Mallinckrodt, B.; Melzig, M.F.; Fuchs, H.; Weng, A. Real-time analysis of membrane permeabilizing effects of oleanane saponins. Bioorg. Med. Chem. 2013, 21, 2387–2395. [Google Scholar] [CrossRef]
Parameter | Untreated | ObiDi/SO1861 |
---|---|---|
alanine aminotransferase | 46.7 ± 17.6 U/L | 59.3 ± 22.5 U/L |
asparagine aminotransferase | 329.3 ± 180.4 U/L | 248.3 ± 187.8 U/L |
glutamate dehydrogenase | 12.7 ± 5.1 U/L | 16.3 ± 6.0 U/L |
cholinesterase | 5837.7 ± 223.4 U/L | 6588.0 ± 548.4 U/L |
creatinine | 0.3 ± 0.0 mg/dL | 0.2 ± 0.1 mg/dL |
ferritin | n.d. 1 | n.d. 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Panjideh, H.; Niesler, N.; Weng, A.; Fuchs, H. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478. https://doi.org/10.3390/toxins14070478
Panjideh H, Niesler N, Weng A, Fuchs H. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins. 2022; 14(7):478. https://doi.org/10.3390/toxins14070478
Chicago/Turabian StylePanjideh, Hossein, Nicole Niesler, Alexander Weng, and Hendrik Fuchs. 2022. "Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861" Toxins 14, no. 7: 478. https://doi.org/10.3390/toxins14070478